Informing our submission for the NICE appraisal of Enhertu
Categories: Personal diagnosis, Secondary breast cancer
Share your experience of being treated with trastuzumab deruxtecan (Enhertu). This will inform our submission to NICE’s appraisal of the drug for treating HER2-positive unresectable or metastatic breast cancer.
What’s the project about?
We are looking for people to help shape our input into the National Institute for Healthcare Excellence’s (NICE) appraisal into trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer.
Enhertu has been available for this group of patients through the cancer drugs fund since 2023, allowing NICE and the pharmaceutical companies to collect more data on its effectiveness. The appraisal will consider whether it should be made routinely available on the NHS.
This decision will affect a different group of patients to the ones we campaigned for in our #EnhertuEmergency campaign.
Who’s organising it?
Name of project lead: Abigail Moir
Job title: Senior policy officer
Organisation: Breast Cancer Now
Email address: policy@breastcancernow.org
Who can take part?
We’re interested to hear from anyone with HER2-positive secondary breast cancer who has received Enhertu.
Why do you want me to be involved?
By sharing your experience of the treatment, you’ll help to shape our input into NICE’s appraisal.
What will you ask me to do?
We’d like you to share your experience of using Enhertu to help inform our submission.
How do I get involved?
If you’d be happy to share your experience, please email us at policy@breastcancernow.org
When’s the deadline?
4 April 2025